Timothy Schmid Sells 33,597 Shares of Johnson & Johnson (NYSE:JNJ) Stock

Key Points

• Johnson & Johnson EVP Timothy Schmid sold 33,597 shares for approximately $9.23 million at an average price of $274.74, reducing his direct holdings by 56.9% to 25,447 shares.
• JNJ shares recently traded near a 12-month high despite a 0.9% decline, while the company reported quarterly EPS and revenue above analysts’ expectations. Johnson & Johnson also declared a quarterly dividend of $1.34 per share, yielding approximately 1.9% annually.
• Wall Street remains broadly positive, with a consensus “Moderate Buy” rating from 25 analysts and an average price target of $272.83; several firms have recently raised their targets, including UBS to $320.

Johnson & Johnson (NYSE:JNJ - Get Free Report) EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Johnson & Johnson Trading Down 0.9%

Johnson & Johnson stock traded down $2.52 during trading hours on Friday, hitting $275.91. The stock had a trading volume of 784,865 shares, compared to its average volume of 8,119,366. The business's 50 day simple moving average is $261.57 and its 200-day simple moving average is $244.85. Johnson & Johnson has a one year low of $173.33 and a one year high of $281.07. The stock has a market cap of $664.92 billion, a price-to-earnings ratio of 31.91, a P/E/G ratio of 2.63 and a beta of 0.24. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. During the same period in the previous year, the business posted $2.77 earnings per share. The business's quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is presently 62.11%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. TD Cowen upped their price target on Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, July 13th. HSBC set a $290.00 price objective on Johnson & Johnson and gave the stock a "buy" rating in a research note on Monday, July 6th. Freedom Capital raised shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Finally, Weiss Ratings raised shares of Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $272.83.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: An analyst upgrade helped JNJ reach a new 12-month high, reinforcing investor confidence in the company’s defensive healthcare profile and growth prospects. Johnson & Johnson Reaches New 12-Month High Following Analyst Upgrade
• Positive Sentiment: UBS raised its price target to $320, implying roughly 16% potential upside from recent levels. The higher target reflects stronger expectations for JNJ’s pharmaceutical pipeline, which could help offset upcoming product pressures. J&J Jumps as UBS Lifts Its Target to $320
• Positive Sentiment: JNJ’s 64-year record of dividend increases remains a key attraction. The company’s diversified businesses and cash generation are viewed as supporting continued dividend growth even as Stelara faces intense competition. Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect
• Positive Sentiment: Analysts collectively maintain a “Moderate Buy” rating, suggesting that Wall Street still sees a favorable risk-reward balance despite the stock’s substantial appreciation. Johnson & Johnson Receives Average Rating of Moderate Buy

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Brighton Jones LLC lifted its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. United Bank raised its holdings in Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company's stock worth $1,539,000 after buying an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock valued at $896,000 after buying an additional 692 shares in the last quarter. Wealth Group Ltd. increased its position in shares of Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock worth $226,000 after acquiring an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. raised its holdings in shares of Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after acquiring an additional 6,584 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source